Assessing the Prognostic Capability of Immune-Related Gene Scoring Systems in Lung Adenocarcinoma

Table 4

Cox regression analysis of the IRG signature and clinical information with lung adenocarcinoma (LUAD) survival.

Variables		Univariable cox				Multivariable cox
		HR	95% CI of HR		P	HR	95% CI of HR		P
			right	left			right	left
GSE31210 (N = 226)
Age	>61 vs. ≤61	1.4	0.73	2.78	0.29	1.38	0.7	2.71	0.35
Sex	Male vs. Female	1.52	0.78	2.96	0.22	1.22	0.63	2.39	0.56
Pathological stage	II vs. I	4.23	2.17	8.23	<0.01	2.07	1.04	4.1	0.03
Signature	High risk vs. low risk	42.31	5.79	309.3	<0.01	32.11	4.32	238.91	<0.01
GSE30219 (N = 83)
Age	>61 vs. ≤61	1.63	0.88	3.01	0.12	1.55	0.83	2.88	0.17
Sex	Male vs. Female	1.37	0.61	3.09	0.44	1.11	0.49	2.56	0.8
T stage	T2 vs. T1	2.14	1.06	4.32	0.03	1.68	0.82	3.42	0.15
Signature	High risk vs. Low risk	2.65	1.39	5.06	<0.01	2.49	1.29	4.78	<0.01
TCGA (N = 400)
Age	>61 vs. ≤61	1.07	0.73	1.56	0.73	1.18	0.8	1.73	0.4
Sex	Male vs. Female	1.03	0.72	1.47	0.87	0.92	0.63	1.33	0.64
Pathological stage	II vs. I	2.48	1.73	3.57	<0.01	2.2	1.52	3.18	<0.01
Signature	High risk vs. Low risk	1.88	1.3	2.7	<0.01	1.73	1.18	2.54	<0.01